Disease Description (Causes and Symptoms)
- Definition summary: Porphyria is a group of diseases caused by the accumulation of intermediate metabolites (δ‑ALA, PBG, various porphyrins, etc.) due to a deficiency or dysfunction of a specific enzyme in the heme synthesis pathway in the blood.
- Pathophysiology:
- Deficiency of a specific enzyme in the heme synthesis pathway (genetic/acquired defect) → accumulation of metabolites.
- Clinical manifestations (acute neurological attacks vs. photosensitive skin lesions) differ depending on the type of accumulated substance and its site of accumulation (liver or bone marrow).
- Acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP) are mainly characterized by neurological symptoms (acute abdominal pain and neuropsychiatric symptoms).
- Cutaneous porphyrias (e.g., porphyria cutanea tarda (PCT), congenital erythropoietic porphyria (CEP), and EPP, which causes true photosensitivity) mainly involve the accumulation of porphyrins in the skin. Sun exposure causes physical and chemical damage, resulting in blisters, skin rupture, pigmentation, and hirsutism.
- Main symptoms:
- Acute forms: Severe abdominal pain, nausea and vomiting, constipation or diarrhea, muscle weakness and sensory abnormalities, anxiety, depression, visual hallucinations, seizures, hyponatremia, etc.
- Cutaneous forms: Blisters, scarring, and fragile skin on areas exposed to sunlight, photosensitivity, hirsutism, changes in skin pigmentation, and oily or reddish-brown discoloration of urine and stool (when porphyrins are excreted).
- Chronic complications include abnormal liver function, increased risk of hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (especially in hepatic porphyrias or when accompanied by liver disease), hemolytic anemia (in some forms), and dental and gum changes (in severe congenital cases).
Treatment Methods and Precautions
- Acute attacks (when neurological symptoms are present)
- Standard treatment: Intravenous heme (globin heme; e.g., the hemin/Normosang/Panhematin group) suppresses the heme synthesis pathway through feedback inhibition, reducing ALA and PBG production.
- Supportive treatment: Suppression of the synthesis pathway with high-carbohydrate intake (high-dose intravenous or oral glucose), strong analgesics (opioids if necessary), antiemetics, fluids and electrolyte correction (especially correction of hyponatremia), and intensive care when respiratory muscle weakness occurs.
- Monitoring for complications: Electrolyte abnormalities, pulmonary embolism, infection, etc.
- Cutaneous porphyrias
- Primary treatment: Avoidance of triggers (alcohol, discontinuation of estrogen preparations, management of iron overload, avoidance of certain medications) and strict sun protection (sunscreen and protective clothing).
- PCT (porphyria cutanea tarda): Reduce porphyrins through regular phlebotomy (periodic blood removal to remove iron) or low-dose chloroquine/hydroxychloroquine (with attention to liver function and dosage). Treat associated underlying conditions (hepatitis C, alcohol use, iron overload, estrogen use, etc.).
- EPP (treatment approved in some regions): Afamelanotide (a melanocortin analog, approved for use in some countries) — reduces photosensitivity. Beta-carotene may help improve phototolerance in some people.
- CEP (severe infantile form): In severe symptomatic cases, curative treatment may be attempted through bone marrow or hematopoietic stem cell transplantation.
- Long-term management and prevention
- Check and avoid high-risk medications (consult a doctor or pharmacist). Porphyria-triggering medications (e.g., some antibiotics, anticonvulsants, sex hormones, and some analgesics) have different levels of risk depending on the type — consultation of a specialized list is necessary.
- Avoid alcohol and smoking, maintain regular meals (avoid fasting), control weight, and test for and manage liver disease (viral hepatitis and iron overload).
- Genetic counseling is recommended (check family history and perform genetic testing if necessary).
- Complications and precautions
- Recurrent acute attacks may leave neurological sequelae (peripheral neuropathy and muscle weakness).
- In hepatic porphyrias, the risk of hepatic fibrosis and liver cancer is increased → regular liver function tests and imaging examinations are recommended.
- Pregnancy, breastfeeding, and female hormone therapy may trigger attacks depending on the type, so consult an obstetrician-gynecologist and a specialist.
Outpatient Visit Checkpoints (Including Items to Prepare and Example Questions)
- Items to prepare (recommended to bring to the doctor’s visit)
- A list of currently used medications (including prescription and nonprescription medications and supplements), as well as a list of medications recently discontinued.
- Copies of previous test results (urine/blood porphyrin, ALA/PBG, liver function, iron studies, genetic testing results, etc.).
- Symptom diary: Timing and duration of attacks, triggers (alcohol, medications, dietary status, etc.), pain intensity, and accompanying symptoms (vomiting, muscle weakness, mood changes, etc.).
- Photos of skin lesions (if present) and changes in urine color.
- Whether you are pregnant or planning a pregnancy, and whether you are breastfeeding.
- Checkpoints before the visit
- Check whether there have been any recent acute attacks and whether symptoms have changed (including whether neurological symptoms are present).
- Record medication use, especially any newly started medications.
- Note potential triggers such as alcohol consumption, hormone use, and weight changes.
- Emergency situations that should be reported to the doctor in advance
- If shortness of breath, rapidly developing muscle weakness (including respiratory muscles), decreased consciousness, or persistent, uncontrollable pain occurs, visit the emergency room immediately.
Examples of General Questions to Ask the Doctor
- What is the exact type of this disease (acute vs. cutaneous), and what are my risk factors?
- Do I need heme (hemin) treatment for my current symptoms? What are the side effects and expected benefits?
- Are there any medications I am taking that I should avoid? What are the alternatives?
- What lifestyle changes can reduce recurrence?
- What is the long-term prognosis (liver disease, neurological sequelae, genetic risk, etc.)?
Examples of Disease-Specific Questions
- If acute attacks recur, what are the indications and expected side effects of intravenous heme (hemin) infusion and preventive treatment?
- For cutaneous forms (PCT/EPP, etc.), which treatment is appropriate in my case: regular phlebotomy or low-dose antimalarial drugs (chloroquine/hydroxychloroquine), and how often should liver function tests be performed?